Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
432 House is a venture creation firm and venture studio focused on building transformative companies at the intersection of human health and sustainability. Founded by Dr. David Berry, a former General Partner at Flagship Pioneering and CEO of Valo Health, the firm utilizes a systematic approach to identify unmet needs and develop novel biological and technological solutions. 432 House operates by conceiving, incubating, and scaling new ventures, often leveraging proprietary platforms in areas such as nutrition, therapeutics, and environmental health. The company aims to address global challenges through a 'biology-first' lens, creating a diverse portfolio of high-impact startups. By integrating scientific innovation with entrepreneurial expertise, 432 House seeks to accelerate the development of products that improve both human and planetary health.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on 432 House.